|
Ana Sofia Coroadinha
Head of Lab
iBET - Instituto de Biologia Experimental e Tecnológica
Oeiras
Portugal
|
Ana Sofia Coroadinha has a Biochemistry degree University of Lisbon) and a PhD in Gene Therapy performed at Généthon (France), Helmholtz Centre for Infection Research (Germany) and iBET Portugal), granted in 2005 by ITQB- NOVA. Since July 2009, she is the head of Cell Line Development and Molecular Virology Lab at Animal Cell Technology Unit, ITQB-NOVA and iBET, Portugal.
Her research aims to provide therapeutic solutions for human healthcare through the use of recombinant virus. The research is anchored on molecular biology, cell biology and applied virology to advance the development of Advanced Therapy Medicinal Products (ATMPs) for gene therapy applications. Focusing on the areas of gene therapy the research comprises the development of expression systems and cell lines for recombinant virus manufacture at high yields and the design of improved viral particles.
Working in Animal Cell Technology since 1997, her PhD contributed to the advance on stable cell line development by incorporating recombination mediated cassette exchange systems for gene therapy gammaretroviral vectors manufacture. She became an auxiliary investigator in 2006 and an independent Researcher (Lab Head) of ITQB-NOVA (New University of Lisbon) in 2009 where she has been contributing in the development and engineering of recombinant virus and cells, namely for the manufacturing of lentiviral, adenoviral and adeno-associated vectors. Recent studies focus on the improvement of vector packaging cargo and vector potency. Additionally, she developed novel tools for viral vector expression, cell line screening and virus detection.
CV Highlights: (i) 68 published papers; 9 book chapters; (ii) 3 patents; (iii) supervised 11 PhD students (8 thesis concluded), 4 post-docs and 20 Master theses (defended); (iv) post-graduation teaching activities at NOVA (PhD and Master Programs) and at several Portuguese Universities; (v) panel reviewer for several international committees (ANR-France, Infect-ERA, Marie Sklodowska-Curie Postdoctoral Fellowships among others); (vi) Editorial member and contribution as referee in several international journals.
Her research aims to provide therapeutic solutions for human healthcare through the use of recombinant virus. The research is anchored on molecular biology, cell biology and applied virology to advance the development of Advanced Therapy Medicinal Products (ATMPs) for gene therapy applications. Focusing on the areas of gene therapy the research comprises the development of expression systems and cell lines for recombinant virus manufacture at high yields and the design of improved viral particles.
Working in Animal Cell Technology since 1997, her PhD contributed to the advance on stable cell line development by incorporating recombination mediated cassette exchange systems for gene therapy gammaretroviral vectors manufacture. She became an auxiliary investigator in 2006 and an independent Researcher (Lab Head) of ITQB-NOVA (New University of Lisbon) in 2009 where she has been contributing in the development and engineering of recombinant virus and cells, namely for the manufacturing of lentiviral, adenoviral and adeno-associated vectors. Recent studies focus on the improvement of vector packaging cargo and vector potency. Additionally, she developed novel tools for viral vector expression, cell line screening and virus detection.
CV Highlights: (i) 68 published papers; 9 book chapters; (ii) 3 patents; (iii) supervised 11 PhD students (8 thesis concluded), 4 post-docs and 20 Master theses (defended); (iv) post-graduation teaching activities at NOVA (PhD and Master Programs) and at several Portuguese Universities; (v) panel reviewer for several international committees (ANR-France, Infect-ERA, Marie Sklodowska-Curie Postdoctoral Fellowships among others); (vi) Editorial member and contribution as referee in several international journals.